TABLE 2.

Results of Kaplan‐Meier and ROC analyses based on different regrouping methods

Regrouping factors	Group	Sample size	HR (95% CI)	Kaplan‐Meier p‐value	AUC	95% CI
Gender	Male	285	2.832 (2.22–3.60)	2.85E‐10	0.925	0.88–0.87
	Female	229	2.238 (1.75–2.86)	2.00E‐05	0.902	0.74–0.97
Age at diagnosis	<45	302	2.145 (1.66–2.78)	5.70E‐05	0.914	0.85–0.96
	≥45	212	2.538 (1.99–3.24)	1.11E‐08	0.895	0.83–0.96
WHO grade	G2	248	2.263 (1.52–3.37)	4.30E‐05	0.878	0.79–0.97
	G3	265	2.122 (1.76–2.56)	2.28E‐07	0.912	0.86–0.96
Histologic subtype	Astrocytoma	194	2.587 (1.97–3.40)	6.08E‐07	0.954	0.91–0.99
	Oligodendroglioma	189	2.169 (1.54–3.05)	4.33E‐04	0.841	0.75–0.93
	Mixed glioma	131	2.366 (1.77–3.16)	2.84E‐04	0.936	0.86–1.00
IDH1 mutation	Yes	91	1.919 (1.13–3.25)	1.03E‐02	0.933	0.81–1.00
	No	34	3.258 (1.48–7.15)	8.46E‐03	1.00	1.00–1.00
Radiation therapy	Yes	277	2.081 (1.71–2.54)	7.31E‐09	0.915	0.87–0.96
	No	169	3.414 (2.72–5.36)	8.00E‐03	0.879	0.77–0.97
Family history of cancer	Yes	132	2.909 (2.01–4.21)	7.50E‐05	0.976	0.94–1.00
	No	210	2.379 (1.81–3.12)	1.50E‐05	0.903	0.84–0.97